Welcome to our dedicated page for Kezar Life Sciences SEC filings (Ticker: KZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kezar Life Sciences, Inc. filings document a clinical-stage biotechnology issuer through material-event reports, capital-structure disclosures, governance matters and corporate-status records. The company’s 8-K filings cover zetomipzomib program updates, operating and financial results, amendments affecting preferred share purchase rights, repayment and termination of a loan agreement, and restructuring costs associated with exit activities.
The filing record also documents completed transaction and status events, including the asset purchase agreement transferring Kezar’s Sec61-based discovery and development program assets, including KZR-261, to Enodia Therapeutics, tender-offer consideration involving cash and contingent value rights, and Nasdaq’s Form 25 notice for removal of Kezar common stock from listing and registration.
Tang Capital Management, Kevin Tang, and affiliated entities report that they no longer own any Kezar Life Sciences common stock. This amendment to their Schedule 13D follows Kezar’s completed merger with Aurinia Pharma U.S., Inc. on May 11, 2026, after which each issued and outstanding Kezar share was cancelled and Kezar became a wholly owned subsidiary of Aurinia. As a result, the reporting persons’ aggregate beneficial ownership is 0 shares, representing 0% of the class, and they ceased to be beneficial owners of 5% or more of Kezar’s common stock as of that date.
Kezar Life Sciences, Inc. — Amendment No. 1 to a Schedule 13G/A was filed by Baselake Partners, LP, Baselake Management, LLC and David Paolella reporting zero beneficial ownership of the issuer's common stock as stated in Item 4. The filing lists the issuer's CUSIP and includes a joint filing statement and signatures dated 05/12/2026.
BML Investment Partners, L.P. filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares of Kezar Life Sciences common stock, representing 0% of the class as of 05/11/2026. The filing states that Braden M. Leonard is the managing member of BML Capital Management, LLC and is deemed an indirect owner of shares held by the partnership, and the reporting persons "disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1)."
Kezar Life Sciences director Courtney Wallace reported the disposition of multiple stock option awards in connection with the company’s merger. On May 11, 2026, five stock option grants covering a total of 21,300 shares of common stock were cancelled at a transaction price of $0.00 per option.
Footnotes explain that, under the Merger Agreement, options with exercise prices at or above a cash amount of $6.955 per share were treated as out-of-the-money and cancelled with no consideration, while in-the-money options were cancelled and converted into rights to receive cash and a contingent value right (CVR) per underlying share.
Kezar Life Sciences, Inc. Chief Operating Officer Mark C. Schiller reported dispositions of his equity in connection with the company’s merger with Aurinia Pharma U.S., Inc. and Aurinia Merger Sub, Inc. On the merger’s effective date, he tendered 2,739 shares of Common Stock into the completed tender offer.
Each tendered share received $6.955 in cash per share plus one non-tradable contingent value right (CVR), providing potential future cash payments if specified milestones are achieved under a CVR Agreement. At the same effective time, all of his employee stock options were automatically cancelled or converted pursuant to the Merger Agreement’s terms, and the filing shows no remaining common shares or stock options held directly after these transactions.
Kezar Life Sciences director Micki Klearman reported the cancellation and disposition to the issuer of several stock option awards in connection with the company’s merger. On May 11, 2026, six option grants covering a total of 23,900 shares of common stock were surrendered back to Kezar.
The options had exercise prices ranging from $4.46 to $26.40 per share and now show zero options remaining after the transactions. Under the Merger Agreement, options with per share exercise prices at or above a cash amount of $6.955 were canceled with no consideration, while in-the-money options with exercise prices below that level were converted into cash payments plus one contingent value right (CVR) for each underlying share.
Kezar Life Sciences, Inc. CEO Christopher J. Kirk reported tendering 43,134 shares of Common Stock in connection with the completion of a cash-and-CVR tender offer by Aurinia Pharma U.S., Inc. Each share received $6.955 in cash, less taxes, plus one non‑tradable contingent value right (CVR) tied to future milestone payments.
The filing also shows dispositions of multiple employee stock options covering various share amounts at exercise prices including $22.80, $6.58, $8.40, $59.10, $23.70 and $14.10 per share. Under the Merger Agreement, out‑of‑the‑money options were cancelled with no consideration, while in‑the‑money options were converted into cash based on the spread over the cash amount plus CVRs for the underlying shares.
Following these tender‑offer and merger‑related transactions, the reported direct holdings for the common shares and the listed options in this filing are shown as zero.
Kezar Life Sciences director Michael Kauffman reported disposing of his remaining equity awards in connection with the company’s merger with Aurinia Pharma U.S., Inc. He tendered 6,369 shares of Common Stock into a completed tender offer, receiving $6.955 per share in cash plus one non-tradable contingent value right (CVR) for each share, as described in the merger terms.
At the merger’s effective time, multiple stock options to buy Kezar common stock were also disposed of back to the issuer. Footnotes state that options with exercise prices at or above the cash amount were cancelled with no payment, while options with lower exercise prices were converted into cash equal to the cash amount minus the strike price for each underlying share, plus one CVR per underlying share. Following these actions, the reported holdings in these securities were reduced to zero.